<DOC>
	<DOC>NCT01533714</DOC>
	<brief_summary>The primary objective of this study is to assess the long-term safety of CDP6038.</brief_summary>
	<brief_title>The Long-term Safety and Efficacy of Olokizumab (CDP6038) With Active Rheumatoid Arthritis</brief_title>
	<detailed_description>Eligible subjects will enter the study after completing the Week 12 Visit of RA0083 [NCT01463059] and will be allowed to continue in this open-label study until approval of the marketing application for the indication of Rheumatoid Arthritis (RA) in the subject's country or region, or until further notice from UCB. All subjects will receive subcutaneous (sc) injections of CDP6038 120 mg every 2 weeks (q2w) throughout the study, regardless of their treatment assignment in RA0083 [NCT01463059].</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Completed the RA0083 [NCT01463059] study (Week 12 Visit) Must have maintained their stable dose (and route) of methotrexate (MTX) between 6 to 16 mg/week in Japan or 7.5 to 20 mg/week in Korea and Taiwan in RA0083 [NCT01463059], and plan to maintain this same dose and route of administration for at least 12 weeks Female subjects must be either postmenopausal for at least 1 year, surgically incapable of childbearing, or effectively practicing 2 acceptable methods of contraception Have an ongoing SAE from the RA0083 [NCT01463059] study Female subjects who are breastfeeding, pregnant, or plan to become pregnant during the study or within 24 weeks Have evidence of active or latent tuberculosis (TB) Subject is receiving any biologic response modifier or synthetic diseasemodifying antirheumatic drug (DMARD) other than MTX Subject has planned surgery during the first 12 weeks of the study Subjects who tested positive for hepatitis B core antibody (HBcAb) and/or hepatitis B surface antibody (HBsAb) at Screening in RA0083 [NCT01463059] and who subsequently test positive for hepatitis B virus deoxyribonucleic acid (HBV DNA) at Week 12 of RA0083 [NCT01463059]</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>Interleukin-6</keyword>
	<keyword>Olokizumab</keyword>
	<keyword>CDP6038</keyword>
</DOC>